CML-423 Trial in Progress: A Phase III Study of Asciminib Vs an Investigator-Selected Tyrosine Kinase Inhibitor (TKI) in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Clinical lymphoma myeloma & leukemia/Clinical lymphoma, myeloma and leukemia（2022）
摘要
MMR at week 48 is the primary endpoint, with MMR at week 96, safety, and deep molecular responses as secondary endpoints.
更多查看译文
关键词
CML,asciminib,first line,TKI,Trial-in-Progress
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要